WaveMan
WaveMan · Company
MLTX · Moonlake Immunotherapeutics
> Search tickers & screens ⌘K
LIVE
← All companies

MLTX MoonLake Immunotherapeutics (MLTX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001821586
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
114
13F, latest reported quarter

What the filings say about MLTX

Insiders, 180 days
-$9.6M net sold
3 sellers · 0% of sales under a 10b5-1 plan

MoonLake Immunotherapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, MoonLake Immunotherapeutics insiders sold a net $9.6M of stock across 97 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Reich Kristian
Chief Scientific Officer
SELL
2026-07-29 SECtraded 2026-07-27
1,100
$22.0K
-37.8%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Jul 22, 2026.
  • The trade is 0.0% of the 2,711,198 shares held after it.
  • 1 other insider sold within 30 days.
  • 114 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Reich Kristian sold about $22.0K of MLTX on Jul 27, 2026; 1 other insider sold within 30 days and 114 funds added in the latest 13F quarter.
Reich Kristian
Chief Scientific Officer
SELL
2026-07-23 SECtraded 2026-07-22
2,448
$49.0K
-37.9%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on Jul 21, 2026.
  • The trade is 0.1% of the 2,712,298 shares held after it.
  • 2 other insiders sold within 30 days.
  • 114 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Reich Kristian sold about $49.0K of MLTX on Jul 22, 2026; 2 other insiders sold within 30 days and 114 funds added in the latest 13F quarter.
Reich Kristian
Chief Scientific Officer
SELL
2026-07-23 SECtraded 2026-07-21
50,000
$1.0M
-37.9%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Jul 20, 2026.
  • The trade is 1.8% of the 2,714,746 shares held after it.
  • 2 other insiders sold within 30 days.
  • 114 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Reich Kristian sold about $1.0M of MLTX on Jul 21, 2026; 2 other insiders sold within 30 days and 114 funds added in the latest 13F quarter.
Reich Kristian
Chief Scientific Officer
SELL
2026-07-21 SECtraded 2026-07-20
43,700
$877.9K
-37.6%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (19 sales), the last on Jul 15, 2026.
  • The trade is 1.6% of the 2,764,746 shares held after it.
  • 2 other insiders sold within 30 days.
  • 114 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Reich Kristian sold about $877.9K of MLTX on Jul 20, 2026; 2 other insiders sold within 30 days and 114 funds added in the latest 13F quarter.
Reich Kristian
Chief Scientific Officer
SELL
2026-07-20 SECtraded 2026-07-15
16,105
$322.3K
-41.1%
Context
  • 18 earlier Form 4 trades (code P or S) here by this insider (18 sales), the last on Jun 17, 2026.
  • The trade is 0.6% of the 2,808,446 shares held after it.
  • 2 other insiders sold within 30 days.
  • 114 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Reich Kristian sold about $322.3K of MLTX on Jul 15, 2026; 2 other insiders sold within 30 days and 114 funds added in the latest 13F quarter.
97 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 92 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$9.6M over 180 days
below 83% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
114 funds bought in last quarter
more than 74% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
14.5% of the float short (float per yahoo 2026-10-26) · 4.2 days to cover · settled 2026-09-30
more than 69% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 15 in the prior 90
Why it matters
The absence is the signal: 15 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch MLTX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+24.8%12M
+0%+45%+89%+134%2025-102025-122026-022026-042026-062026-082026-10 2026-03-31 · LAMPERT MARK N sold $32.4M2026-03-31 · LAMPERT MARK N sold $26.3M2026-03-31 · LAMPERT MARK N sold $4.2M2025-12-08 · Santos da Silva Jorge sold $2.0M2025-12-08 · Reich Kristian sold $2.0M2026-04-10 · Santos da Silva Jorge sold $1.8M2026-04-09 · Bodenstedt Matthias sold $1.6M2026-07-10 · Santos da Silva Jorge sold $1.4M2025-12-09 · Reich Kristian sold $1.1M2025-12-09 · Santos da Silva Jorge sold $1.0M2026-07-21 · Reich Kristian sold $1.0M2026-06-17 · Reich Kristian sold $971.5K2026-07-01 · Santos da Silva Jorge sold $956.9K2026-04-13 · Santos da Silva Jorge sold $945.6K2026-06-15 · Reich Kristian sold $944.5K2026-06-16 · Reich Kristian sold $935.0K2026-07-20 · Reich Kristian sold $877.9K2026-06-22 · Bodenstedt Matthias sold $862.2K2026-07-09 · Santos da Silva Jorge sold $679.1K2026-07-15 · Reich Kristian sold $322.3K2026-06-17 · Bodenstedt Matthias sold $296.8K2026-05-11 · Bodenstedt Matthias sold $273.3K2026-06-18 · Bodenstedt Matthias sold $54.8K2026-07-22 · Reich Kristian sold $49.0K2026-04-14 · Bodenstedt Matthias sold $47.5K2026-04-10 · Bodenstedt Matthias sold $37.6K2026-07-27 · Reich Kristian sold $22.0K2026-07-15 · Reich Kristian filed to sell $2.9M2026-06-30 · Santos da Silva Jorge filed to sell $3.0M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MLTX: institutional holders (13F)

13F holdings, latest reported quarter
BVF INC/IL
16,001,284 sh
$311.5M
Deep Track Capital, LP
6,999,025 sh
$136.3M
D. E. Shaw & Co., Inc.
3,365,507 sh
$65.5M
Cormorant Asset Management, LP
3,205,433 sh
$62.4M
Jupiter Topco LLC
3,085,906 sh
$60.1M

Congress trades in MLTX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MLTX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Reich Kristian
Filed 2026-07-15
$2.9M
Santos da Silva Jorge
Filed 2026-06-30
$3.0M

MLTX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALPS Medical Breakthroughs ETF
$1.4M position · as of 2026-05-31
0.9%
T. Rowe Price Health Care ETF
$152.3K position · as of 2026-06-30
0.7%
Virtus Biotech Clinical Trials Etf
$306.7K position · as of 2026-07-31
0.7%
Invesco Dorsey Wright SmallCap Momentum ETF
$1.5M position · as of 2026-05-31
0.4%
Harbor Active Small Cap Growth ETF
$82.8K position · as of 2026-07-31
0.3%
Nomura Healthcare Fund
$2.1M position · as of 2026-06-30
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $9.6M sold by insiders over 180 days, 114 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

MLTX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$225.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.23x
long-term 2026-06-30 plus current 2022-12-31 (42 months older than the period end); equity 2026-06-30
Cash flow to debt
-2.26x
TTM operating cash flow over long-term 2026-06-30 plus current 2022-12-31 (42 months older than the period end)
Return on equity
-67.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-51.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-55.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$626.7M
market value at close 2026-10-26 on 2026-08-01 shares, plus long-term 2026-06-30 plus current 2022-12-31 (42 months older than the period end), minus cash 2026-06-30
FCF yield
-22.4%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$244.8M-$143.1M-$54.1M-$65.1M
Net income-$227.3M-$118.9M-$36.0M-$50.0M
EPS (diluted)-3.53-1.89-0.73-1.70
Operating cash flow-$196.0M-$116.6M-$42.8M-$55.9M
Cash$334.5M$180.4M$451.2M$39.5M
Long-term debt$74.1M$0n/an/a
Buybacksn/a$50$0$0
SEC XBRL, fiscal years, as known on 2026-10-28

MLTX Stock Sonar score 5/7 axes

Find similar shapesCompare

MLTX ranks highest on institutional and government (74th percentile) and profitability (44th), and lowest on insider conviction (7th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
44
Inputs
  • Return on equity-67.4% · 44 pct, sector of 545
  • Return on assets-51.0% · 43 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-55.8% · 45 pct, sector of 576
Financial health
42
Inputs
  • Debt to equity0.23x · 42 pct, sector of 352
  • Cash flow to debt-2.26x · 42 pct, sector of 371
Insider conviction
7
Inputs
  • Net Form 4 buying (codes P and S), 180d-$9.6M · 15 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
74
Inputs
  • Funds adding, latest quarter114 · 74 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
26
Inputs
  • Short interest, % of float+14.5% · 26 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

MLTX filings, in plain words

Are MoonLake Immunotherapeutics insiders buying or selling MLTX?

In the 180 days to 2026-10-28, MoonLake Immunotherapeutics insiders were net sellers, a net $9.6M across purchases and sales reported on Form 4, by 3 sellers.

Read the full summary

In the 180 days to 2026-10-28, MoonLake Immunotherapeutics insiders were net sellers of MLTX, a net $9.6M across purchases and sales reported on Form 4 by 3 sellers. None of the 15 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies